1.20
-0.01(-0.83%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.18 |
| Day High | 1.24 |
| Day Low | 1.13 |
| 52-Week High | 41.2 |
| 52-Week Low | 0.95 |
| Volume | 24,627 |
| Average Volume | 80,154 |
| Market Cap | 2.58M |
| PE | -0.09 |
| EPS | -13.81 |
| Moving Average 50 Days | 2.03 |
| Moving Average 200 Days | 4.72 |
| Change | -0.02 |
If you invested $1000 in HCW Biologics Inc. (HCWB) since IPO date, it would be worth $190.48 as of January 14, 2026 at a share price of $1.2. Whereas If you bought $1000 worth of HCW Biologics Inc. (HCWB) shares 3 years ago, it would be worth $13.68 as of January 14, 2026 at a share price of $1.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 19, 2025 1:30 PM GMT
MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health sp
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
GlobeNewswire Inc.
Nov 18, 2025 12:25 PM GMT
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflamma
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune checkpoint inhibitor designated as Company’s franchise immunotherapeutic for internal clinical developmentMIRAMAR, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (th